| Ytd | 19.99% | |
| 1y | 648.16% |
| Open | 372.26 | Prev Close | 370.16 | Low | 352.31 | High | 377.48 | Mkt Cap | 10.32B |
| Vol | 184.54K | Avg Vol | 480.33K | EPS | -12.93 | P/E | -28.63 | Forward P/E | -35.51 |
| Beta | 2.78 | Short Ratio | 7.27 | Inst. Own | 117.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 305.56 | 200-d Avg | 287.74 | 1yr Est | 610.05 |
PRAX News
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ul
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully i
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully i
Bank of New York Mellon Corp raised its holdings in Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
Fifth Third Bancorp bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX)
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully i
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pr
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
Praxis Precision Medicines Inc. (NASDAQ:PRAX) said on Monday that the U.S. Food and Drug Administrat
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAV
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conf
Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in e
BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully i
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully i
Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 s
Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the main go
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary succes
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 202
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
